Unlearn is pioneering technology company using AI-generated digital twins of individual patients to revolutionize medical research.

Unlearn.AI is dvancing artificial intelligence to eliminate trial and error in medicine.

Unlearn.AI was founded in 2017 by Jonathan Walsh, Aaron Smith, and Charles Fisher. The company is headquartered in San Francisco, California, with an office in Cambridge, MA.

Unlearn.AI is the only company creating TwinRCTs™, a randomized trial that uses machine learning and historical data to achieve a higher probability of success with a smaller number of patients.

Unlearn's technology is regulatory-qualified and used by leading global pharmaceutical companies to run AI-powered clinical trials that reach full enrollment faster and bring new treatments to patients sooner.

Unlearn won approval from the European Medicines Agency (EMA) in September 2022 for using its AI-driven approach for conducting smaller and quicker clinical trials and struck several multi-million dollar deals with pharmaceutical companies, including Merck, Darmstadt, among others.

Unlearn is backed by Insight Partners, Mubadala Capital Venture, 8VC, DCVC, Radical Ventures, Wittington Ventures, DCVC Bio, and others. The company raised $15M in a new round on Mar 21, 2023. This brings Unlearn's total funding to $84.8M to date.